Tarsus Achieves Strong Third Quarter Financial Results, Driven by Growing Xdemvy Prescriptions

IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) a biopharmaceutical company focused on the development and commercialization of therapeutic eyecare treatments, has announced financial results for the third quarter ended September 30, 2025. Net product sales for the quarter were reported at $118.7 million, compared with $48.1 million for the same period in 2024, driven by more than 103,000 bottles of Xdemvy delivered to patients compared with more than 41,400 bottles delivered to patients in the same period in 2024, the company advised. Xdemvy (lotilaner ophthalmic solution) 0.25%, approved by the FDA in July 2023, is a novel prescription eye drop designed to treat Demodex blepharitis.